Opioids and their receptors are key players in a cross-talk between the nervous and immune systems. For example, the endogenous opioid system is activated during inflammation as a physiological feedback mechanism to attenuate inflammatory pain. Herein, we report that in primary human T lymphocytes, Raji B cells, U937 monocytes, primary human polymorphonuclear leukocytes, and mature dendritic cells, the proinflammatory cytokine tumor necrosis factor induced -opioid receptor gene transcription. Transcriptional induction of the gene in immune cells was mediated via tumor necrosis factor receptor type 2. Using selective in vivo disruption of possibly involved transcription factors with decoy oligonucleotides, nuclear factor-B was identified as the factor responsible for induction of the gene in immune cells, whereas activator protein-1 was found to be uninvolved. Nuclear factor-B also mediates upregulation of -opioid receptors in neuronal cells stimulated with tumor necrosis factor. Among six putative nuclear factor-B binding sites on the -opioid receptor gene promoter, three cis-active elements at nt Ϫ2174, Ϫ557, and Ϫ207 were identified using transfection experiments of reporter gene constructs, electrophoretic mobility shift assays, and in vivo binding studies with decoy oligonucleotides. An allelic variation within the Ϫ557 element significantly reduced its trans-activating potency, which may affect regulation of the -opioid receptor gene in persons carrying this mutation. This study suggests a regulatory function of tumor necrosis factor in opioid-mediated processes in neuronal and immune cells, with possible impact on the complex of inflammation-induced analgesia.
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Opioids are typically associated with phenomena such as analgesia, respiratory depression, euphoria, and addiction, which are mediated by three different opioid receptors termed , ␦, and (Kieffer, 1995) . In connection with the immune system, endogenous opioids, such as ␤-endorphin, and exogenous opioids, such as morphine, are potent immunomodulators with inhibitory, and stimulatory effects on immune function. These include lymphoid organ atrophy, changes in CD4 ϩ and CD8 ϩ expression in thymocytes, reduced natural killer cell activity (Weber and Pert, 1989; Gaveriaux-Ruff et al., 1998) , the balance between T helper type 1 and type 2 cells (Roy et al., 1999; Sacerdote et al., 2000) , lipopolysaccharide-induced production of IL-6 and TNF, activity of the transcription factor NFB in macrophages and peripheral blood mononuclear cell cultures (Chao et al., 1993; Roy et al., 1998a) , and chemotactic responsiveness in thymocytes (McCarthy et al., 2001) . These findings indicate the presence of -opioid receptors on various immune cells, because morphine binds preferentially this receptor subtype. The hypothesis that -opioid receptors are expressed on immune cells is further supported by recent observations demonstrating that endomorphins, which are extremely selective for this receptor subtype, have diverse immunomodulatory properties as well (Azuma and Ohura, 2002) . However, transcription of -opioid receptors in immune effector cells does not proceed constitutively; rather, it is regulated by cytokines such as IL-1 (Vidal et al., 1998) and IL-4 (Kraus et al., 2001) .
The cytokine TNF regulates a plethora of vital functions in the whole body, under both physiological and pathophysiological conditions (e.g., inflammation). Evidence for alterations within the opioid system in inflammation, which include changes in the levels of endogenous opioid peptides, as well as their receptors, is presented in numerous reports (Stein et al., 1990; Czlonkowski et al., 1993; Ji et al., 1995; Pol et al., 2001; Buzas et al., 2002; Cahill et al., 2003 ). An earlier study demonstrated that TNF up-regulates -opioid receptors in neuronal cells via the transcription factor NFB; however, a detailed promoter analysis identifying binding sites for this factor remains to be done (Börner et al., 2002) .
Here, we addressed the question of whether TNF induces transcription of -opioid receptors in immune effector cells, and we investigated molecular mechanisms of this regulation. The most prominent transcription factors modulating target genes in response to TNF are NFB and AP-1 (Baud and Karin, 2001 ). Using an approach in which function of selected transcription factors can be specifically disrupted in vivo by decoy oligonucleotides, we directly identified NFB as the responsible transcription factor for TNF induction of -opioid receptor transcription in immune cells. Finally, NFB binding sites were localized on the human -opioid receptor gene promoter to link the action of this transcription factor to transcriptional regulation of the gene in neuronal and immune cells.
Materials and Methods
Cell Culture, Reagents, Antibodies, and Cytokines. Isolation and cultivation of all primary immune cells, cultivation of Raji and U937 immune cell lines, and maturation of dendritic cells, have been described in detail (Kraus et al., 2001) . All cytokines and the antihuman TNFR1 and TNFR2 antibodies (mab225 and mab226) were purchased from R&D Systems (Wiesbaden, Germany). Cycloheximide (Sigma, Taufkirchen, Germany) was used at a concentration of 10 g/ml. Sulfasalazine (Sigma) was dissolved in cell culture medium and added at a concentration of 1 mM 30 min before TNF.
Conventional RT-PCR from Human Immune Effector Cells. Total RNA was extracted using RNeasy columns (QIAGEN, Hilden, Germany) and checked for accidental degradation on an agarose gel. Two micrograms were used for cDNA synthesis with Moloney murine leukemia virus reverse transcriptase, RNase HϪ (Promega, Mannheim, Germany), and diluted to 100 l. GAPDH control RT-PCR, and amplification of -opioid receptor-specific transcripts has been described in detail previously (Kraus et al., 2001) .
Quantitative Real-Time PCR. Real-time RT-PCR with Raji and U937 cDNAs was performed according to the supplier's manual in a total volume of 20 l on a LightCycler instrument using the LightCycler fast-start DNA master SYBR green I kit (both from Roche, Mannheim, Germany). To calculate the amounts of -opioid receptor transcripts relative to the housekeeping gene GAPDH, a 163-bp fragment of this gene was amplified (forward primer 5Ј-CAACTA-CATGGTTTACATGTTC-3Ј, reverse primer 5Ј-GCCAGTGGACTC-CACGAC-3Ј, located on different exons) under the following conditions: 1) preincubation for 7 min at 95°C; 2) 50 cycles for 5 s at 95°C, 5 s at 64°C, and 10 s at 72°C. -Opioid receptor transcripts were amplified as follows: 1) preincubation for 8 min at 95°C. 2) 50 cycles for 5 s at 95°C, 10 s at 65°C, and 18 s at 72°C. The sequences of -opioid receptor primers were 5Ј-GATCATGGCCCTCTACTCCA-3Ј (located at position 216 in exon 1) and 5Ј-GCATTTCGGGGAGTACG-GAA-3Ј (located at position 557 in exon 2, to avoid amplification of genomic DNA).
Reporter Gene Plasmids. Construction of the human -opioid receptor promoter reporter constructs Ϫ2624, Ϫ2229, Ϫ1372, Ϫ779, Ϫ2478/Ϫ2287, and Ϫ1854/Ϫ1224 has been described earlier (Kraus et al., 2001; Börner et al., 2002) . The 5Ј-end deletion constructs Ϫ1854, Ϫ254, and Ϫ174 were made by cutting the Ϫ2624 plasmid with HindIII and AccI, PstI, and BlpI, respectively, and religation of the blunted ends. For the Ϫ2229/Ϫ1854 construct, a SauI-AccI fragment of the human -opioid receptor upstream region was inserted in front of the Herpes simplex virus tk promoter of pBLCAT2 (Luckow and Schutz, 1987) . Plasmids Ϫ1372/Ϫ910, Ϫ910/Ϫ714, Ϫ714/Ϫ590, and Ϫ590/Ϫ363 were generated by digestion of the -opioid receptor promoter with Sau3A and shotgun cloning of the fragments into pBLCAT2's BamHI site. Insertion of oligonucleotides into pBLCAT2 was performed according to a described method (Kang and Inouye, 1993) . All plasmids were sequenced from both sides to ensure correct orientations and sequences of the inserts.
Transfection Experiments. Plasmid DNA was isolated using QIAGEN plasmid kits. Before transfection, cells received fresh medium with 1% fetal calf serum. Raji and U937 cells were transfected as follows: 5 ϫ 10 6 cells were pelleted, resuspended in 5 ml of medium, and transfected by drop-wise addition of 10 g of plasmid DNA in 500 l of a buffer containing 125 mM CaCl 2 , 140 mM NaCl, 25 mM HEPES, and 0.5 mM Na 2 HPO 4 , pH 7.05. After a 17-h incubation at 3% CO 2 and 35°C, cells were pelleted again and given fresh medium. SH SY5Y monolayer cells were transfected by the same procedure, but without centrifugation steps. Transient expression of CAT reporter gene products was allowed for a further 48 h with or without 100 U/ml TNF. The CAT enzyme-linked immunosorbent assay (Roche) was performed according to the supplier's manual.
Decoy Oligonucleotide Approach in Immune Cells. Generally, in the decoy approach, double-stranded oligonucleotides with specific binding sequences for transcription factors are brought into living cells to selectively disrupt the function of these factors. In the cells, transcription factors then interact with an excess of decoy oligonucleotides instead of binding to the natural regulatory motifs of genes (Bielinska et al., 1990; Kraus et al., 2003) . Decoy oligonucleotides (100 nM) were directly cotransfected either with reporter gene plasmid DNA (for the experiments shown in Figs. 4 and 7) or carrier DNA (the promoterless cloning vector pBLCAT3, for the experiments shown in Fig. 3 ). The oligonucleotides had no chemical modifications. To avoid any effect on transfection efficiency caused by different amounts of transfected DNA, the total amounts of both plasmid DNA and oligonucleotides were kept constant in the individual experiments by addition of oligonucleotides containing an AP-2 binding site, if necessary. To exclude unspecific effects of decoy oligonucleotides that might be a result solely of their presence, the following controls were performed: 100 nM oligonucleotides containing motifs for transcription factors AP-1, AP-2, or STAT6 did not change inducibility of a NFB-responsive reporter construct; singlestranded NFB oligonucleotides were not active as decoys (100 nM sense or antisense strand, or a mixture of 100 nM each of nonannealed sense and antisense strand). Oligonucleotides used are shown in Table 1 .
Extraction of Nuclear Proteins and Electrophoretic Mobility Shift Assay. Both procedures have been described recently (Börner et al., 2002) . For immunoshift experiments, the p65 NFB antibody C-20 (Santa Cruz Biotechnology, Heidelberg, Germany) was used. 
Results

TNF Induces Transcription of the -Opioid Receptor Gene in Various Human Immune Effector Cells. Primary T cells and polymorphonuclear leukocytes, the cell lines
Tumor Necrosis Factor Induces -Opioid Receptors
877
at ASPET Journals on August 16, 2017 molpharm.aspetjournals.org
Raji (B cells), U937 (monocytes), and HMEC-1 (microvascular endothelial cells), and, in addition, mature CD83 ϩ dendritic cells were used to study the effect of TNF on the expression of the -opioid receptor gene in immune effector cells (Fig. 1A) . The human cell line SH SY5Y (neuroblastoma), which is known to express -opioid receptors constitutively, served as control. No -opioid receptor-specific transcripts could be detected in any of the unstimulated immune cells, even though the highly sensitive nested PCR technique was used. This technique allows detection of as few as approximately five copies of a template, as revealed in control experiments (data not shown). Contrasting with this, -opioid receptor gene transcription was strongly induced in all immune cells tested after stimulation of the cells with TNF for 16 h. The amounts of -opioid receptor transcripts in the stimulated immune cells were 5 to 20 times less than in the SH SY5Y cells, as revealed by quantitative real-time PCR (data not shown). The following experiments were designed to investigate in greater detail the mechanisms underlying the TNF regulation in Raji cells. Studying the time course, real-time PCR revealed that transcription of the gene initiates between 2 and 6 h after TNF-stimulation (Fig. 1B) . Cycloheximide had no effect on TNF-induced transcription of the -opioid receptor gene (Fig. 1B) .
TNFR2 Mediates Induction of -Opioid Receptor Transcription in Raji Cells. Neutralizing antibodies against TNFR1 (p55, TNFRSF1A) and TNFR2 (p75, TNFRSF1B) were used to determine the TNFR by which the effect on -opioid receptor gene transcription is mediated (Fig. 2) . These antibodies lack agonistic properties, which has been observed for some TNFR antibodies, and are suitable to neutralize effects of TNF (Matthews and Neale, 1987) . Addition of TNFR1 antibodies before stimulation of Raji cells with TNF had no inhibitory effect. In contrast, -opioid receptor transcription was blocked in a concentration-dependent manner by TNFR2 antibodies, suggesting that the TNF effect is mediated solely via the TNFR2.
Induction of -Opioid Receptor Transcription in Immune Cells Depends on NFB, but Not on AP-1. Next, we addressed the question of whether the transcription factor AP-1 or NFB, or possibly both, mediates TNF-induction of -opioid receptor transcription. We used an approach that combined selective disruption of transcription factor function using AP-1 and NFB decoy oligonucleotides and quantitative real-time PCR to monitor -opioid receptor-specific transcripts (Fig. 3) . Consistent with the results shown in Fig. 1 , no -opioid receptor transcripts were observed in unstimulated Raji and U937 cells (data not shown). TNF-induced -opioid receptor transcription in these cells is displayed in curves 1 and 5 (Fig. 3) . This TNF-induced transcription was negligibly affected by decoy oligonucleotides containing an AP-1 binding site (curves 2 and 6), suggesting that AP-1 is not involved in mediating the TNF effect. In contrast, loss of NFB function by transfection of NFB decoy oligonucleotides completely inhibited transcriptional induction of the -opioid receptor gene in TNF-stimulated immune cells (Fig.  3, curves 3 , 4, 7, and 8), which directly demonstrates that the Fig. 1 . TNF induces -opioid receptor transcription in human immune effector cells. A, detection of transcripts in immune cells. cDNAs from TNF-stimulated (100 U/ml for 16 h; ϩ) and unstimulated (Ϫ) Raji B cells, primary T cells, and polymorphonuclear leukocytes (PMN), U937 monocytes, mature dendritic cells (DC), microvascular endothelial cells (HMEC-1), and neuroblastoma cells (SH SY5Y, controls) were subjected to RT-PCR. The arrow indicates -opioid receptor-specific 342-bp amplification products using amounts of cDNAs that produced comparable amounts of GAPDH amplificates. A typical gel is shown. M, HaeIIIdigested X174 size marker (band-sizes from top to bottom: 1353 bp, 1078 bp, 872 bp, 603 bp, and 281/217 bp double band). B, time kinetic of -opioid receptor transcription initiation in Raji cells and effect of cycloheximide. Raji cells were stimulated with 100 U/ml TNF for different times as indicated. The 24-h incubations were tested with and without cycloheximide (CX). RNA and cDNA were prepared and subjected to real-time RT-PCR. The relative amounts of -opioid receptor mRNA at the different time points are plotted after normalization to equal GAPDH mRNA levels. The results are from two independent experiments performed in triplicate. TNF effect is dependent on NFB. Controls demonstrating the efficacy and specificity of the decoy oligonucleotides are displayed in Fig. 4 . Therefore, a reporter gene construct containing a classic NFB binding motif was cotransfected in Raji cells together with various decoy oligonucleotides (Fig.  4A) . Then, the decoy oligonucleotide-provoked inhibition of the TNF-/NFB-mediated reporter gene activity was measured. Homologous NFB decoys resulted in a dose-dependent inhibition of reporter gene activity (IC 50 , 47 nM). The specificity of NFB decoy oligonucleotides is shown in Fig. 7 with NFB-like motifs with mutations within the binding sequence. AP-1, AP-2, and STAT6 decoys did not inhibit reporter gene activation. Figure 4B shows similar controls for an AP-1-responsive reporter gene construct with wild type (IC 50 , 45 nM) and mutant AP-1 and NFB decoy oligonucleotides. The finding that the TNF-induced transcription of the -opioid receptor gene is entirely blocked by NFB decoy oligonucleotides implies that almost all cells were transfected with the decoys, which is unlikely, because the transfection rate of these cells in our experiments was lower than 50%. However, we observed that the decoy oligonucleotides were entering the cells also without transfection, by simple addition into the medium. Thus, addition of NFB decoys to culture medium immediately before TNF stimulation resulted in a decrease in TNF-induced -opioid receptor mRNA in Raji cells in a dose-dependent manner, as revealed by quantitative real time PCR, 24 h after stimulation: TNFstimulated control cells, 100 Ϯ 9% -opioid receptor transcripts; TNF-stimulated cells grown in medium containing 25 nM decoy oligonucleotides, 145 Ϯ 39%; 50 nM decoys, 111 Ϯ 15%; 75 nM decoys, 75 Ϯ 14%; 100 nM decoys, 9 Ϯ 3%**. Thus, both passive uptake of the decoy oligonucleotides and transfection of them contributes to the highly efficient inhibition of TNF-induced -opioid receptor transcription in our experiments.
The Human -Opioid Receptor Gene Promoter Contains Three NFB Binding Sites. Transient transfection experiments with reporter gene constructs containing sequences of the -opioid receptor promoter were performed to identify NFB elements. SH SY5Y cells were used for these experiments, because stimulation of these cells with TNF results only in activation of NFB, not, for example, AP-1, for which the promoter is responsive as well (Börner et al., 2002) . As suggested by sequence homology, the -opioid receptor promoter contains six motifs to which NFB may bind. These putative elements, termed M1 through M6, are shown in Fig. 5A and their sequences are shown in Fig. 7A . Transfection of the longest promoter construct, Ϫ2624, revealed significant inducibility with TNF (Fig. 5A, lane 1) . Consecutive 5Ј-end deletion of the promoter up to Ϫ254 did not abolish inducibility (lanes 2 to 6). However, the Ϫ174 construct showed no responsiveness to TNF (Fig. 5A, lane 7) , indicating that M6 at position Ϫ207 may be an NFB site. To identify additional NFB elements and to determine whether these elements would be functional in front of a heterologous promoter, the -opioid receptor upstream sequences were dissected and tested in front of the Herpes simplex virus tk promoter. These experiments showed that sequences containing M2 (at nt Ϫ2174) and M5 (at nt Ϫ557) also conferred Fig. 3 . TNF-induction of -opioid receptor transcription in immune cells depends on NFB but not AP-1. Real-time RT-PCR monitoring amplification of -opioid receptor transcripts in Raji and U937 cells after stimulation with 100 U/ml TNF for 16 h (curves 1 and 5, as indicated below). The other samples contained cDNAs from TNF-stimulated cells that were transfected with decoy oligonucleotides specific for AP-1 and/or NFB transcription factors (100 nM each) as indicated below. NFB decoy oligonucleotides completely inhibited TNF-induced transcription of the gene. All samples were transfected with equal amounts of oligonucleotides (an unrelated AP-2 oligonucleotide was used to adjust the amount). Inset, amplification of mRNA of the GAPDH gene. A typical experiment (of three) is shown. Downloaded from a response to TNF, whereas other sequences and the other motifs did not (Fig. 5A, lanes 8 to 14) . The reporter gene vector pBLCAT2 was not responsive to TNF (Fig. 5A, lane  15) . When oligonucleotides containing M2, M5, and M6 sequences were cloned in front of the tk promoter, they were sufficient to mediate the TNF response independent of their orientation (Fig. 5B) . Treatment of transfected cells with the specific NFB inhibitor sulfasalazine (Wahl et al., 1998) before TNF stimulation abolished the effect of the cytokine (data not shown), which further supports the conclusion that these elements bind NFB. In a previous study, polymorphisms of the human -opioid receptor gene had been localized (Hoehe et al., 2000) . Interestingly, one of these naturally occurring allelic variation alters the sequence of the Ϫ557 M5 motif from 5Ј-GGGGTTTTAG-3Ј to 5Ј-GGGATTTTAG-3Ј. To test whether this variation may have any impact on its transactivating potency, a construct containing the mutated allele was also tested. The mutated motif also conferred a significant response to TNF but with a significantly reduced potency compared with the wild-type sequence (Fig. 5B) . The -Opioid Receptor Promoter Elements Bind NFB in Vitro. Electrophoretic mobility shift assays were performed to investigate binding of NFB to the putative sites within the -opioid receptor gene promoter (Fig. 6) . First, oligonucleotides containing M1 through M6 were tested to determine whether they were able to compete for NFB binding to a classic NFB element. In addition to homologous NFB oligonucleotides, M2, M5 (wild type), and M6 were efficient competitors (Fig. 6A) , indicating that they are indeed NFB sites. This is in good accordance with the transfection experiments described above. To compare the wild-type M5 and the polymorphic M5 motif, the same experiments were performed using multiple amounts of competitor DNA (Fig. 6B) . Clearly, the ability to compete for NFB binding was more pronounced for the wild-type motif, with a complete competition using 3.3 pmol of oligonucleotides. In contrast, using the mutated M5 motif, 10 pmol of oligonucleotides was needed for a complete competition.
Then, M2, M5 wild type, M5 variant, and M6 oligonucleotides were used as probes and tested for NFB binding (Fig.  6C) . The band-shift patterns were identical for the three -opioid receptor motifs as well as for the classic NFB motif, yielding a typical double band. The -opioid receptor elements were confirmed as NFB binding sites by competition experiments with classic NFB oligonucleotides as well as by supershift experiments with a specific NFB antibody (Fig.  6D) .
The -Opioid Receptor Promoter Elements Bind NFB in Intact Raji Cells. The decoy oligonucleotide approach was used to demonstrate binding of the -opioid receptor elements to NFB in intact cells. For these experiments, a reporter gene construct containing a classic NFB binding motif was cotransfected in Raji cells together with decoy oligonucleotides containing the -opioid receptor NFB sequences (Fig. 7A) . In full accordance with the transfection and gel-shift experiments, the M2, M5 (wt), and M6 sequences were targets for NFB in the immune cells and inhibited TNF-induced stimulation of the reporter gene construct by capturing NFB in vivo. The effect of the polymorphism within element M5 could also be demonstrated with the decoy approach in Raji cells (Fig. 7B) . Thus, wild-type M5 decoy oligonucleotides were significantly more effective competitors than mutated M5 decoys, with 44 and 55 nM concentrations of oligonucleotides, respectively, needed for a 50% inhibition of TNF-induced reporter gene activation.
Discussion
Multiple immunomodulatory effects of opioids are transduced to immune effector cells mainly via three mechanisms: either indirectly via the central nervous system [e.g., by activation of the hypothalamus-pituitary-adrenal axis (Cabot et al., 2001; Roy et al., 2001) ], directly via atypical opioid receptors [which were postulated because some opioid effects cannot be blocked by the classic opioid receptor antagonist naloxone (Roy et al., 1998b) ], or directly via the classic opioid receptor subtypes , ␦, and present on immune cells. It has been shown previously that classic -opioid receptors are induced by IL-4 in various immune cells (Kraus et al., 2001) and by IL-1 in endothelial cells (Vidal et al., 1998) . Here, we demonstrated that TNF also induces -opioid receptor transcription in immune cells. Considerable evidence indicates that transcription of -opioid receptors is correlated with expression of functional receptors on immune cells, demonstrated by the capacity of -opioid receptor ligands to affect Fig. 6 . The -opioid receptor promoter elements bind NFB in vitro. Electrophoretic mobility shift assays were performed using various probes (indicated below the gels) and competitor DNAs or p65 NFB antibody (indicated above the gels) with nuclear extracts of TNF-stimulated SH SY5Y cells. A, like homologous NFB oligonucleotides, the putative -opioid receptor motifs M2, M5 (wild type), and M6 compete for binding to NFB. Molar excesses of approximately 5-and 50-fold (1 and 10 pmol) of competitor DNA are indicated by wedges. B, the wild type (wt) M5 motif binds NFB with higher affinity than the polymorphic (po) M5 motif (lanes 1 and 6, 100 fmol competitor DNA; lanes 2 and 7, 333 fmol; lanes 3 and 8, 1 pmol; lanes 4 and 9, 3.3 pmol; lanes 5 and 10, 10 pmol) C, NFB binding to the -opioid receptor motifs M2, M5 wt and po, and M6 is competed by classic NFB oligonucleotides. D, immunoshift experiments demonstrate that the -opioid receptor motifs M2, M5 wt and po, and M6 are NFB elements. S, supershifted band. Typical gels representing at least three experiments are shown.
Tumor Necrosis Factor Induces -Opioid Receptors 881
at ASPET Journals on August 16, 2017 molpharm.aspetjournals.org immune cell functions described in numerous reports (Weber and Pert, 1989; Chao et al., 1993; Roy et al., 1998a; Gaveriaux-Ruff et al., 1998; Roy et al., 1999; Sacerdote et al., 2000; McCarthy et al., 2001; Azuma and Ohura, 2002) . In addition to cells derived from the immune system, cytokines regulate -opioid receptor expression also in neuronal cells. Thus, induction of -opioid receptor expression is observed in primary astrocyte-enriched cultures of various brain regions by IL-1 (Ruzicka et al., 1996) and in primary fetal cortical neurons and SH SY5Y cells by IL-4 (Kraus et al., 2001 ) and TNF (Börner et al., 2002) . Studies with IL-6 knockout mice revealed that levels of -opioid receptors are decreased in certain brain regions compared with wild-type animals, suggesting also a positive regulation of the gene by IL-6 (Bianchi et al., 1999) . From the current point of view, cytokines thus represent potent physiological modulators of -opioid receptor transcription.
Transcriptional activation of -opioid receptors in response to TNF in Raji cells is dependent on TNFR2 and independent of de novo protein synthesis, although transcripts appear somewhat delayed after 2 to 6 h. To date, the physiological role of TNFR2 is not completely understood. It is clear, however, that TNFR2 can trigger inflammation (Tartaglia et al., 1991; Akassoglou et al., 2003) . The involvement of -opioid receptors in inflammation is discussed below. By and large, TNF may lead to activation of two major transcription factors, AP-1 and NFB (Baud and Karin, 2001) . Both factors could also be involved in TNF regulation of -opioid receptor transcription because the gene promoters of various species contain functional AP-1 elements as well (Kraus et al., 1995; Börner et al., 2002) . Interestingly, an involvement of AP-1 could be clearly ruled out in the immune cell lines used, whereas loss of NFB function completely inhibited induction of the gene, demonstrating that transcriptional induction of the gene in response to TNF depends solely on NFB.
The decoy oligonucleotide strategy to selectively disrupt function of a transcription factor in intact cells, which was used here, allows direct identification of the relevant factor(s) involved in a particular regulatory event. It is thus very useful to close the common gap between measuring an effect of a stimulus on a certain gene's transcription on the one hand and the identification of "possibly involved" transcription factor binding sites on that gene's promoter on the other hand.
Multiple NFB elements on the -opioid receptor gene most probably indicate the importance for regulation via this factor. Interestingly, the trans-activating potency of one of the NFB regulatory elements is markedly reduced because of an allelic variation. Currently, two mechanisms are being discussed to explain the well known heterogeneity of patients' responses to opioid analgetics: multiple protein variants of opioid receptors and opioid receptor gene polymorphisms. The -opioid receptor gene is expressed in a considerable number of protein variants (Pan et al., 2001) and has plenty of polymorphisms (Hoehe et al., 2000) . Notably, 28 allelic variations, more than half of the polymorphisms identified so far on this gene, are located within the promoter region. Promoter polymorphisms may have considerable consequences for regulation of the gene if they affect binding sites for transcription factors. Interestingly, apart from the polymorphism within the NFB site described here, another allelic variation is located within a STAT6 element, which impairs regulation of the gene by cytokines like IL-4 (Kraus et al., 2001 ). Another polymorphism is located at nt Ϫ1699, immediately adjacent to a binding site for a still unknown nuclear protein (Börner et al., 2002) .
It should be noted that transcription of the -opioid receptor gene in mice is under control of two distinct promoters. In addition to the main promoter flanking exon 1, there is another promoter flanking exon 11, which is located roughly 10 kilobases upstream of exon 1 (Pan et al., 2001) . For the human gene, only the promoter upstream of exon 1 is known so far. Nevertheless, even if there is no evidence to date that the human gene is alternatively spliced in a similar way, the existence of an upstream promoter of the human gene cannot be excluded.
Regulation of -opioid receptors by TNF may be important within the complex of inflammation-induced analgesia. It is now established that immunocyte-derived endogenous opioids induce analgesia by activating peripheral opioid recep- Fig. 7 . The -opioid receptor promoter elements bind NFB in immune cells. A, M2, M5 (wt), and M6 but not M1, M3, and M4 decoy oligonucleotides bind NFB in Raji cells and attenuate TNF inducibility. Top, TNF inducibility (right, reported as -fold induction) of a reporter gene construct containing a classic NFB response element (left). Bottom, cotransfection of this construct together with decoy oligonucleotides (100 nM each) containing the putative -opioid receptor NFB sites (left) and their effect on TNF inducibility (right). B, wild-type M5 decoy oligonucleotides attenuate TNF inducibility more efficiently than polymorphic M5 decoys. The experimental design is similar to that shown in Fig. 7A . Here, increasing amounts of cotransfected wild type and polymorphic M5 decoy oligonucleotides inhibit TNF induction of the classic NFB reporter gene construct (control) in Raji cells. Fold induction of the reporter construct (6.2-fold equals 0% inhibition, 1.0-fold equals 100% inhibition) is plotted against the concentration of cotransfected decoy oligonucleotides. The results of at least three independent transfection experiments performed in triplicate plus S.E.M. are displayed. (***, p Ͻ 0.001) tors at later stages during inflammation, which can be regarded as a physiological mechanism to counteract and reduce inflammatory pain (Stein et al., 1990; Cabot et al., 1997) . Most probably, the relevant opioid receptors are of the subtype, because these are up-regulated in dorsal root ganglia in inflammation, whereas the ␦ subtype is downregulated (Ji et al., 1995) . Moreover, it was shown that cytokines such as TNF, IL-1␤, IL-6, and corticotropin-releasing factor contribute to inflammation-induced analgesia (Czlonkowski et al., 1993; Schafer et al., 1994) . In this scenario, TNF could contribute to maximizing the analgesic effect of endogenous opioids by increasing the concentration of their receptors in the neuronal cells. In the immunocytes, TNF-induction of -opioid receptors could allow a feedback regulation in which the endogenous opioids could modulate either their own secretion or secretion of other cytokines.
A strategy to relieve pain in patients with rheumatoid arthritis is to inhibit TNF and/or NFB, which are recognized as key mediators for this disease. Interestingly, use of decoy oligonucleotides to disrupt NFB activity has also been discussed for gene therapy of rheumatoid arthritis (Tomita et al., 2000) . We demonstrated that chemically nonmodified decoy oligonucleotides could enter blood cells without being transfected or transduced via viruses, which could be promising toward certain decoy gene therapies. Often, NFB inhibitors, such as sulfasalazine (Wahl et al., 1998) , or preparations of antibodies against TNF, such as infliximab (Kalden, 2002) , are applied. In the end, the strategy to block TNF/NFB may bear considerable side effects. These could include impaired antinociception as a result of the lack of natural activation of the opioid system via TNF and NFB. Especially in the case of rheumatoid arthritis, it may be not beneficial to impair the opioid system, because a recent study demonstrated that endogenous opioids ameliorate excessive synovial cell functions via -opioid receptors (Takeba et al., 2001 ). The authors speculated that endogenous opioids act in an antinociceptive as well as an antiinflammatory manner.
In conclusion, our study contributes to the understanding of the multiple interactions between the immune system and the nervous system and suggests additional functions of TNF in physiological and pathophysiological regulatory circuits.
